The kinetic and mechanistic study of levetiracetam oxidation with chloramine-B in acid medium
World Journal of Biology Pharmacy and Health Sciences, 13 (1):
331-338 (January 2023)DOI: 10.30574/wjbphs.2023.13.1.0041
Abstract
The medicine levetiracetam, marketed under the brand name Keppra, is approved by the Food and Drug Administration, used to treat seizures. It belongs to a class of drug known as anticonvulsants. The current work uses sodium-N-chloro-benzene sulfonamide or chloramine-B to evaluate the kinetics and mechanistic of levetiracetam at 308 K in HCl medium. (CAB). The reaction has a first-order dependence on CAB0 and substrate0, as well as a fractional-order dependence on the concentration of HCl. Changes in ionic strength or the adding of benzene sulfonamide have no effect on the rate. We looked at the effect at five temperatures. The Arrhenius plots were used to evaluate the thermodynamic parameters. The reaction stoichiometry was found 1:2, and chromatographic and spectroscopic studies anticipated the oxidation product imine. The probable mechanism back up the above-mentioned findings. The relevant rate law has been determined because of all these discoveries.